Cromakalim, a potassium channel opener, ameliorates the organophosphate and carbamate-induced seizure in mice by Ostadhadi, S. et al.
 ORIGINAL ARTICLE  
 
Corresponding Author: A.R. Dehpour  
Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran  
Tel: +98 21 88973652, Fax: +98 21 88973652, E-mail address: dehpour@yahoo.com 
 
Cromakalim, a Potassium Channel Opener, Ameliorates the Organophosphate 
and Carbamate-Induced Seizure in Mice 
Sattar Ostadhadi1,2, Abouzar Moradi3, Samira Zolfaghari2, Vahid Nikoui4, and Ahmad Reza Dehpour1,2 
1 Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran 
2 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran 
3 Department of Periodontics, School of Dentistry, Alborz University of Medical Sciences, Alborz, Iran 
4 Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran 
 
Received: 02 Nov. 2016; Accepted: 12 Dec. 2017 
 
Abstract- Organophosphates (OPs) and carbamates are acetylcholine esterase inhibitors (AChEIs), which 
can cause seizure and lethality. Anticonvulsant properties of potassium channel openers including 
cromakalim have been determined in previous studies. In the present experiment, the possible effect of 
cromakalim on the convulsion and death induced by OPs and carbamates was studied in mice. Dichlorvos (an 
OP, 50 mg/kg) and physostigmine (a carbamate, 2 mg/kg) were used to induce seizure in animals. 
Cromakalim at doses of 0.1, 10, and 30 µg/kg was injected 30 min before dichlorvos and physostigmine, and 
5 min before glibenclamide (a potassium channel blocker, 1 mg/kg) administration. All injections were 
performed intraperitoneally. After drugs administration, the onset of convulsion, death, the severity of 
seizure, and rate of mortality were investigated. Results revealed that both dichlorvos and physostigmine 
induced seizure activity and lethality in 100% of the animals. Cromakalim at doses of 0.1, 10, and 30 µg/kg 
significantly increased the latency of both seizure and death (P<0.05). Also, cromakalim decreased the 
mortality rate induced by dichlorvos and physostigmine (P<0.05). On the other hand, glibenclamide blocked 
all aspects of the anticonvulsant effect of cromakalim (P<0.05). This study revealed for the first time that 
cromakalim (a KATP channel opener) diminishes the seizure and death induced by dichlorvos and 
physostigmine in mice, and introduces a new aspect to manage the patients who suffer from OPs/carbamates-
induced seizure.  
© 2018 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2018;56(1):14-20. 
 




Organophosphates (OPs) and carbamates have 
primarily been employed as pesticides in agriculture (1). 
Some kinds of OPs have shown therapeutic properties 
and have been used as drugs for the treatment of some 
neurologic disorders including Alzheimer's disease (2). 
Both agricultural and medical usages of OPs and 
carbamates are attributed to their ability to disrupt the 
function of the cholinergic nervous system by inhibiting 
acetylcholine esterase (AChE) (3). This enzyme is 
responsible for the hydrolysis of acetylcholine (ACh) in 
physiological condition; thus, its blockade leads to the 
ACh accumulation in the nervous system (2). 
 In humans, poisoning with OPs/carbamates may 
result in convulsions (4). The cellular mechanisms by 
which these agents induce seizure are not fully 
understood (5). Because of that, there is no effective 
treatment to manage patients suffering from 
OPs/carbamates-induced seizure. Although past studies, 
relying on the disruption of the cholinergic system due 
to these chemicals, suggest the use of atropine, oximes, 
and benzodiazepines to control this kind of seizure, all 
such treatments are not satisfactory and showed severe 
adverse effects (6,7). Hence, the mechanisms of action 
of seizure induction by OPs and carbamates must be 
explained and the importance of such studies to discover 
new therapies and drugs with favorable pharmacologic 
properties and side effect profile is unquestionable.  
Potassium ion (K+) channels may play an important 
role in the control of all features of neuronal excitability 
including resting membrane potential (8). The opening 
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of K+-channels is expected to hyperpolarize neurons and 
inhibit action potential firing and prevent hyper-
synchronous neuronal discharges, which occur during a 
seizure (9,10). Therefore, K+-channel opening is one of 
the potential anti-epileptic mechanisms (11,12). On the 
other hand, past reports have shown that KATP channels, 
one of the different types of K+ channel family, play an 
important role in the management of seizure threshold in 
several in vitro and in vivo models (13,14). These 
findings have been confirmed by other clinical trials 
(15). However, there is no study to show the protective 
effects of K+-channel openers on seizure induced by OPs 
and carbamates.  
This study was carried out to investigate the possible 
effect of cromakalim (a potassium channel opener) on 
OP and carbamate-induced seizure in mice. Therefore, 
dichlorvos and physostigmine sulfate were used in this 
experiment as an OP and carbamate, respectively, to 
induce seizure in mice, and the possible effect of 
potassium channel openers on convulsion was examined 
using cromakalim. 
  
Materials and Methods 
 
Animals 
In total, 120 male Naval Medical Research Institute 
(NMRI) mice weighing 20-26 g were used in the 
experiments. Animals were housed in a room with 
controlled temperature (21-22° C), light (12-h light/dark 
cycle), and humidity (50±10%). Animals were allowed 
free access to standard laboratory, food and water. 
Assignment of subjects to experimental groups (n=10 in 
each group) was randomized. The tests were performed 
between 9 a.m. and 1 p.m. The experimental procedures 
used throughout this study were in compliance with the 
guidelines for the Care and Use of Animals and were 
approved by the Local Ethics Committee on Animal 




The following drugs were used in the experiments: 
dichlorvos (50 mg/kg) as an OP, physostigmine sulfate 
(2 mg/kg) as a carbamate, cromakalim (0.1, 10, and 30 
µg/kg) as a potassium channel opener, and 
glibenclamide (1 mg/kg) as a potassium channel 
blocker. As previously reported, this dose of 
glibenclamide (1 mg/kg) and its vehicle (dimethyl 
sulfoxide [DMSO]), did not alter the plasma glucose 
levels, significantly (9). Dichlorvos (2, 2-chlorovinyl 
dimethyl phosphate) was prepared from the Institute of 
Organic Chemistry (Waster green, Iran). Physostigmine 
sulfate, cromakalim, and glibenclamide were purchased 
from Sigma-Aldrich (USA). Dichlorvos was mixed with 
powdered acacia and distilled water in a dry mortar, as 
described previously (16). Glibenclamide was dissolved 
in DMSO. Physostigmine and cromakalim were 
dissolved in saline. Dosages of all drugs were based on 
the weight of their salt forms. 
 
Experimental design  
Dichlorvos and physostigmine were administrated 
intraperitoneally (i.p.) to animals to induce seizure. Two 
experimental groups (dichlorvos-treated and 
physostigmine-treated) were divided into three 
categories: 
To investigate the possible role of potassium 
channels in the seizure induced by OP and carbamate, 
we used cromakalim and glibenclamide:  
(a) Cromakalim (0.1, 10, and 30 µg/kg) was 
administrated intraperitoneally 30 minutes before 
OP/carbamate administration.  
(b) Glibenclamide (1 mg/kg) was administrated 
intraperitoneally 30 minutes before OP/carbamate 
injection.  
(c) Further, to determine the effect of cromakalim in 
seizure induced by OP/carbamate, cromakalim at dose 
30 µg/kg (as an effective dose) was administrated 5 
minutes before glibenclamide (10). 
 
Behavioral assessments 
Animals were monitored for 120 minutes after drug 
injections. Seizures were evaluated and scored based 
on the staging system defined by McLean et al., (5,17). 
It will define stage 0 if there is no abnormal behavior; 
In stage 1 some abnormal behaviors including 
salivation, chewing, and pawing of mouth were 
observed; Stage 2, dazed appearance, intermittent 
motionlessness, tremor, and/or bobbing of the head 
was observed; Stage 3, like Stage 2, random and/or 
generalized jerks are seen; Stage 4, intermittent rearing 
on hind legs with forepaws extended without falling; 
Stage 5 is same as the stage 4, with falling to the side 
or rear; Stage 6, status epilepticus was observed. 
Stages 1-3 and 4-6 were considered as sub-convulsive 
and convulsive behaviors, respectively. The latency of 
seizures after injection of drugs (in seconds), the 
latency to onset of death within one hour (in seconds), 
mortality after injection (percentage) within one hour, 
and stages of seizures induced by injection of drugs 
(percentage) were recorded. 
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Data analysis 
Data were analyzed using GraphPad Prism software, 
version 5 (USA). Comparisons between experimental 
and control groups were performed by one-way 
ANOVA followed by Tukey’s post-hoc when 





Dichlorvos and physostigmine administration 
cause convulsion and death in mice 
Both dichlorvos (50 mg/kg, i.p.) and physostigmine 
(2 mg/kg, i.p.) result in seizure activity in mice (Table 
1). In these groups, convulsion and death (Table 1) 
occurred in 100% of the animals. 
 
Effect of cromakalim on the onset of seizure/death 
induced by dichlorvos and physostigmine 
Pretreatment with cromakalim at doses of 10 µg/kg 
(P<0.05 for physostigmine, P<0.01 for dichlorvos) and 
30 µg/kg (P<0.01 for dichlorvos and physostigmine) 
increased the latency time of clonic seizure (Figure 1) 
and also prevented the dichlorvos- or physostigmine-
induced seizures in mice (Table 1). 
 
 
Figure 1. Effect of different doses of cromakalim (0.1, 10, and 30 µg/kg) and glibenclamide (1 mg/kg) on the starting time of seizure after 
dichlorvos (50 mg/kg) and physostigmine (2 mg/kg) injection 
Effect of cromakalim (30 µg/kg) and glibenclamide (1 mg/kg) co-administration on the onset of seizure in mice). Values are shown as 
mean+S.E.M. of 10 animals. #P<0.05, ##P<0.01 compared physostigmine-injected group (control). **P<0.01 compared dichlorvos-injected group 
(control). ***P<0.001 compared to cromakalim (30 µg/kg) + glibenclamide (1 mg/kg) -administrated group. 
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Table 1. Effect of different doses of cromakalim and glibenclamide on the stages of seizure induced by 
dichlorvos (50 mg/kg) and physostigmine (2 mg/kg). Data are shown as percentage of mice, (𝑛=10). Each 
stage’s definition is described in section 2.4. 
Treatment Stage of seizures 
Treatment Organophosphate Stage 0 Stage 1-3 Stage 4-6 
Cromakalim 0 
Dichlorvos 0 0 100 
Physostigmine 0 0 100 
Cromakalim 0.1 
Dichlorvos 10 10 80 
Physostigmine 10 20 70 
Cromakalim 10 
Dichlorvos 40 20 40 
Physostigmine 50 20 30 
Cromakalim 30 
Dichlorvos 80 10 10 
Physostigmine 80 10 10 
Glibenclamide 1 
Dichlorvos 0 0 100 
Physostigmine 0 0 100 
Cromakalim 30 + 
Glibenclamide 1 
Dichlorvos 0 10 90 
Physostigmine 10 10 80 
 
 
Also, cromakalim at doses of 0.1 µg/kg (P<0.01), 10 
µg/kg (P<0.001), and 30 µg/kg (P<0.001) significantly 
increased the onset of death after both OP and carbamate 
administration (Figure 2). 
 
 
Figure 2. Effect of different doses of cromakalim (0.1, 10, and 30 µg/kg) and glibenclamide (1 mg/kg) on the latency of death after dichlorvos 
(50 mg/kg) and physostigmine (2 mg/kg) injection 
Effect of cromakalim (30 µg/kg) and glibenclamide (1 mg/kg) co-administration on the onset of seizure in mice. Values are shown as 
mean+S.E.M. of 10 animals. &&P<0.01, &&&P<0.001 compared to dichlorvos-injected group (control).  **P<0.01 and ***P<0.001 compared to 
physostigmine-injected group (control). ***P<0.001 compared to cromakalim (30 µg/kg) + glibenclamide (1 mg/kg) -administrated group. 
 
Effect of cromakalim on the mortality induced by 
dichlorvos and physostigmine 
Figure 3 shows that cromakalim administration 
reduces the percentage of mortality induced by 
dichlorvos and physostigmine. Cromakalim at doses of 
0.1, 10, and 30 µg/kg decreased the mortality percentage 
compared to control group, which received dichlorvos 
and physostigmine.  
 
Anticonvulsant effects of cromakalim 
18    Acta Medica Iranica, Vol. 56, No. 1 (2018)   
 
Figure 3. Effect of different doses of cromakalim (0.1, 10, and 30 µg/kg) and glibenclamide (1 mg/kg) on the mortality rate after dichlorvos (50 
mg/kg) and physostigmine (2 mg/kg) injection 
Effect of cromakalim (30 µg/kg) and glibenclamide (1 mg/kg) co-administration on the mortality rate in mice. Data are shown as percentage of 
mice (𝑛 = 10). 
 
Effect of cromakalim on the seizure stages after 
dichlorvos and physostigmine administration 
Demonstrating in Table 1, cromakalim at doses of 
0.1, 10, and 30 µg/kg reversed the proconvulsant effect 
of both dichlorvos and physostigmine in mice. This 
anticonvulsant effect of the potassium channel opener, 
cromakalim shows a dose-dependent pattern, since by 
increasing the dose of this agent the percentage of stage 
0 and stage 1-3 raised compared to the control group 
(Table 1). 
 
Effect of glibenclamide on the anticonvulsant effect 
of cromakalim 
Administration of glibenclamide (1 mg/kg, i.p.) 5 
minutes before cromakalim injection (30 µg/kg) 
inhibited the anticonvulsant effect of cromakalim on 
OP- and carbamate-induced seizure (Table 1). It also 
decreased the latency time of clonic seizure (P<0.001) 
(Figure 1) as well as death time after injection (P<0.001) 
(Figure 2). Furthermore, glibenclamide increased the 




Dichlorvos and physostigmine cause colonic and 
tonic seizure and ultimately death in 100% of animals. 
After intraperitoneal injection of dichlorvos or 
physostigmine, some degree of tremor and excessive 
activity appear and then the symptoms become more 
severe and cause death over the time. Seizure is one of 
the toxic effects that happens following being poisoned 
with OPs and carbamates such as dichlorvos and 
physostigmine (18,19). These substances induce their 
effects by inhibiting the AChE in the nervous system. 
Depending on the level of AChE inhibition, cholinergic 
activation may cause hyperactivity of excitable tissues, 
fasciculations, seizures, convulsions, coma, and death 
(20). It has been suggested that systemic application of 
sub-lethal doses of AChE inhibitors (AChEIs) may 
result in seizures, convulsions, and central nervous 
system (CNS) lesions (21). These findings corroborate 
our results, which showed that dichlorvos at dose of 50 
mg/kg as well as physostigmine at dose of 2 mg/kg 
cause convulsion and death in all animals. 
Based on intervention with cholinergic system by 
these chemicals, past studies suggested using atropine, 
oximes, and benzodiazepines to control this kind of 
seizure. However, drugs typically used against epilepsy 
in the hospital are ineffective against OP/carbamates 
intoxication (6). For example, atropine improves only a 
few toxicity symptoms and shows severe adverse effects 
(22). Oximes permeate weakly through the blood-brain 
barrier (23), and they cannot treat the CNS toxicity, 
effectively. Benzodiazepines are likely to depress 
brainstem respiratory and circulatory centers (7). In this 
regard, conducting research to discover new anti-
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epileptic drugs, which can inhibit the seizure induced by 
OPs and carbamates with favorable pharmacologic 
properties and side effect profile is unquestionable.  
In our study, cromakalim, a potassium channel 
opener, reduced the rate of both seizure and mortality. 
The onset of seizure and death after OP/carbamate 
administration was diminished by cromakalim 
pretreatment and this is in agreement with previous data, 
which showed that diazoxide as an ATP-sensitive 
potassium channels opener exerted anticonvulsant 
activity against dichlorvos-induced seizure (5). Also, in 
the present study, glibenclamide as an ATP-sensitive 
potassium channels blocker, reversed the anticonvulsant 
effect of cromakalim. 
Potassium (K+) channels are a large family of ion 
channels. Among the different kinds of K+ channels, 
ATP-sensitive K+ (KATP) channels are involved in 
numerous physiological functions (8). KATP channels are 
located pre- and post-synaptically in many brain areas 
and their function is controlled by the metabolic 
condition of the neuron. They open and close in reply to 
the alterations in intracellular ATP/ADP relations. Low 
ATP degree opens these channels, leading to K+ efflux 
and cell hyperpolarization (24). The hyperpolarization 
induced by KATP channels opening inhibits the action 
potential firing and prevents hyper-synchronous 
neuronal discharges which occur during seizure. In this 
regard, it has been shown that KATP channels play a 
significant role in regulation of seizure threshold in 
several in vitro and in vivo models (13,14,25). Also, 
KATP channel openers have been reported to decrease 
excitability in CA3 hippocampal cells (26), and show 
antiepileptic effects in a model of drug-induced epilepsy 
(27). Molecular studies have shown that functional KATP 
channels are octameric complexes consisting of four 
inward rectifier K+ channel sub-units (Kir 6.1 or Kir 6.2) 
and four sulfonylurea receptor sub-units (SUR1, SUR2A 
or SUR2B) (11). Mice which lack expression of either 
the SUR1 gene or the Kir 6.1 gene are susceptible to 
seizures (28). Moreover, it has been shown that mice 
with deficiencies in a subunit of KATP channels (Kir 
6.2−/− mice) are vulnerable to generalized seizure (14). 
Also, it has been recently reported that KATP channel 
openers such as cromakalim and diazoxide increase the 
clonic seizures induced by pentylenetetrazol (PTZ) in 
mice (9,29).  
Altogether, the role of potassium channel openers in 
the seizure has been shown in several clinical and 
animal studies. Nevertheless, the effect of these agents 
on the seizure induced by OPs and carbamates has not 
been reported yet. Therefore, we studied this matter, and 
our results revealed that cromakalim (KATP channel 
opener) at doses of 0.1, 10, and 30 µg/kg could reverse 
the convulsion and death following OPs/carbamates 
administration. Moreover, our data revealed that anti-
epileptic effect of cromakalim could be reversed by 
glibenclamide (a K+ channel blocker). These data 
confirm the role of potassium channels in mediating the 
proconvulsant effect of OPs and carbamates. These 
findings make it possible to introduce new aspect with 
specific targets to manage patients who suffer from OPs 
or carbamates toxicity.  
In summary, this study shows for the first time that 
cromakalim (KATP channel opener) diminished the 
seizure induced by dichlorvos and physostigmine in 
mice. We also suggest using new aspect with specific 
targets to manage seizures from OPs/carbamates 
toxicity, although further investigation is needed to 
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